Many consider moral decisions to follow an internal "moral compass", resistant to social pressures. Here we examine how social influence shapes moral decisions under risk, and how it operates in different decision contexts. We employed an adapted Asian Disease Paradigm where participants chose between certain losses/gains and probabilistic losses/gains in a series of moral (lives) or financial (money) decisions. We assessed participants' own risk preferences before and after exposing them to social norms that are generally risk-averse or risk-seeking. Our results showed that participants robustly shifted their own choices towards the observed risk preferences. This conformity holds even after a re-testing in three days. Interestingly, in the monetary domain, risk-averse norms have more influence on choices in the loss frame, whereas risk-seeking norms have more influence in the gain frame, presumably because norms that contradict default behavior are most informative. In the moral domain, risk-averse as opposed to risk-seeking norms are more effective in the loss frame but in the gain frame different norms are equally effective. Taken together, our results demonstrate conformity in risk preferences across contexts and highlight unique features of decisions and conformity in moral and monetary domains.

[This corrects the article DOI: 10.3389/fpsyt.2022.1011585.].

BACKGROUND: The prevalence of alcohol consumption in Poland is estimated to be as high as 80% of the adult population. The use of stimulants is the second most common reason for seeking addiction treatment. However, treatment outcomes remain unsatisfactory, as 40-85% of individuals who complete various treatment programs relapse and fall back into addiction within 2 years following program completion. METHODS: The 13-armed randomized controlled trial aimed to assess the effectiveness of a mobile app-based self-guided psychological intervention delivered via a smartphone app (Nałogometr) in reducing craving and lapse risk in problematic alcohol or stimulants use. Participant recruitment and data collection will be performed from June 2022 to September 2022. The 4-week mobile intervention program will include short-term and long-term intervention modules based mainly on mindfulness and cognitive-behavioral therapy. Intervention effectiveness assessment will include Ecological Momentary Assessment. That is, we will collect longitudinal data on a set of characteristics of day-to-day functioning. The primary outcomes will include a self-reported number of lapses and addiction craving level. In contrast, the secondary outcomes will be the severity of problematic substance use, anxiety and depression scores, and life satisfaction scores. CONCLUSION: This study will establish how mobile app-based self-guided psychological interventions can help reduce craving and lapse risk in alcohol and stimulant dependence. If successful, this randomized controlled trial (RCT) may provide an innovative, easily available, and cost-effective mHealth approach for craving and lapse risk in substance addictions. CLINICAL TRIAL REGISTRATION: [https://clinicaltrials.gov/], identifier [NCT054 34429].

BACKGROUND: The prevalence of substance and behavioral addiction is estimated between 10 and 15% of the global population and remains a severe public health concern. Moreover, addiction treatment has several barriers, such as a lack of access to professional treatment or stigmatization. Mobile health interventions emerge as a promising solution. METHODS: This two-armed randomized controlled trial (RCT) aims to assess the efficacy of a mobile app-based self-guided psychological intervention delivered via a smartphone app (Nałogometr) in reducing craving and lapse risk in problematic behaviors and substance use compared to a control condition. Participant recruitment and data collection will start in June 2022 and end in September 2022. Due to the nature of the study, i.e., a nationwide study of problematic substance use and behaviors, we will aim to recruit all individuals willing to participate. The four-week intervention condition includes short-term and long-term modules based mainly on mindfulness and cognitive behavioral therapy. Longitudinal data on several variables related to craving and lapse risk are collected daily using ecological momentary assessment (EMA). The primary outcomes of interest will be the self-reported number of lapses and craving level in daily EMA. Moreover, a questionnaire battery assessment is administered at baseline in the first week following onboarding, after five weeks, and after six months. The secondary outcome measures will include the severity of problematic substance use or behaviors, anxiety and depression, and life satisfaction. RESULTS: Results will be submitted for publication in peer-reviewed journals. CLINICAL TRIAL REGISTRATION: [https://clinicaltrials.gov/], identifier [NCT054 34,429].

BACKGROUND: Substance Use Disorder (SUD) persists as a significant public health challenge worldwide, with an estimated prevalence of approximately 10-15% across the global populace. This condition is characterized by a notably high risk of lapses and relapses, even subsequent to treatment interventions. Mobile health interventions, owing to their widespread accessibility, emerge as a promising approach to diminish the risk of relapse post-treatment and to broaden the scope of care, especially in regions with a scarcity of trained medical professionals. METHOD: This study is designed to assess the effectiveness of mobile interventions in mitigating cravings and preventing lapses among individuals diagnosed with SUD. Employing a two-armed, randomized controlled trial framework, the study will evaluate a self-administered psychological intervention delivered through a mobile application, Nałogometr 2.0. Over a period of three months, participants will engage with intervention modules that primarily incorporate mindfulness techniques and Cognitive Behavioral Therapy (CBT) principles. Ecological Momentary Assessment (EMA) will be utilized to gather longitudinal data on a range of variables that are indicative of craving intensity and the risk of lapse. In addition to this, a monthly-administered battery of questionnaires will be employed to gauge the severity of substance dependence, as well as to measure levels of anxiety, depression, and overall life satisfaction. RESULTS: Results will be submitted for publication in peer-reviewed journals. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier [NCT05730504].